David Amsellem Analyst Performance

Senior Research Analyst at Piper Sandler

David Amsellem is a stock analyst at Piper Sandler focused in the medical sector, covering 43 publicly traded companies. Over the past year, David Amsellem has issued 32 stock ratings, including strong buy, buy, and hold recommendations. While full access to David Amsellem's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Amsellem's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 283 Last 11 Years
Buy Recommendations: 64.06% 180 Buy Ratings
Companies Covered: 43 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.4%	1 ratings
Buy	63.7%	178 ratings
Hold	28.1%	79 ratings
Sell	7.8%	22 ratings

Out of 281 total stock ratings issued by David Amsellem at Piper Sandler, the majority (63.7%) have been Buy recommendations, followed by 28.1% Hold, 7.8% Sell, and 0.4% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
HZNP
Aug 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
AVDL
May 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	83.7% of companies on NASDAQ	36 companies
NYSE	16.3% of companies on NYSE	7 companies

David Amsellem, an analyst at Piper Sandler, currently covers 43 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 40 companies	93.0%
	Miscellaneous 3 companies	7.0%

David Amsellem of Piper Sandler specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
PHARMACEUTICAL PREPARATIONS 18 companies	41.9%
MED - BIOMED/GENE 7 companies	16.3%
MED - DRUGS 7 companies	16.3%
MED - GENERIC DRG 4 companies	9.3%
Miscellaneous 3 companies	7.0%
MEDICAL SERVICES 2 companies	4.7%
LARGE CAP PHARMA 1 company	2.3%
SURGICAL & MEDICAL INSTRUMENTS 1 company	2.3%

About David Amsellem

David Amsellem is a managing director and senior research analyst at Piper Sandler covering biotechnology. Amsellem has more than 20 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Prior to joining Piper Sandler in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-2008 and a senior associate on the biotechnology equity research team from 2003-2006. Amsellem earned a Bachelor of Science degree from Cornell University.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
SUPN Supernus Pharmaceuticals	8/29/2025	Boost Price Target	$45.26	$40.00	Neutral
AMGN Amgen	8/25/2025	Boost Price Target	$289.76	$342.00	Overweight
BIIB Biogen	8/14/2025	Boost Price Target	$133.65	$118.00	Neutral
ABBV AbbVie	8/12/2025	Initiated Coverage	$198.46	$231.00	Overweight
ABBV AbbVie	8/11/2025	Upgrade	$204.78		Strong-Buy
ANIP ANI Pharmaceuticals	8/8/2025	Reiterated Rating	$81.68	$94.00	Overweight
AMPH Amphastar Pharmaceuticals	8/8/2025	Lower Price Target	$21.62	$25.00	Neutral
CORT Corcept Therapeutics	8/1/2025	Lower Price Target	$67.17	$121.00	Overweight
NBIX Neurocrine Biosciences	7/31/2025	Boost Price Target	$132.66	$175.00	Overweight
AMGN Amgen	6/27/2025	Reiterated Rating	$280.30	$328.00	Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
SAGE Sage Therapeutics	6/17/2025	Downgrade	$9.10	$8.50	Hold
BIIB Biogen	6/12/2025	Reiterated Rating	$132.02	$115.00	Neutral
AMGN Amgen	5/16/2025	Lower Price Target	$271.02	$328.00	Overweight
OGN Organon & Co.	5/15/2025	Lower Price Target	$8.75	$18.00	Overweight
COLL Collegium Pharmaceutical	5/9/2025	Reiterated Rating	$28.47	$37.00	Neutral
JAZZ Jazz Pharmaceuticals	5/7/2025	Reiterated Rating	$104.84	$147.00	Overweight
NBIX Neurocrine Biosciences	5/6/2025	Reiterated Rating	$120.29	$154.00	Overweight
BMY Bristol Myers Squibb	4/22/2025	Initiated Coverage	$48.95	$65.00	Overweight
CORT Corcept Therapeutics	4/3/2025	Boost Price Target	$83.81	$131.00	Overweight
AMPH Amphastar Pharmaceuticals	3/21/2025	Lower Price Target	$27.94	$32.00	Neutral
OPTN OptiNose	3/21/2025	Reiterated Rating	$9.12	$9.00	Neutral
XERS Xeris Biopharma	3/7/2025	Reiterated Rating	$4.36	$4.00	Neutral
INDV Indivior	3/6/2025	Lower Price Target	$10.01	$13.00	Overweight
VTRS Viatris	3/5/2025	Reiterated Rating	$9.60	$10.00	Neutral
CORT Corcept Therapeutics	2/27/2025	Boost Price Target	$63.37	$78.00	Overweight
JAZZ Jazz Pharmaceuticals	2/26/2025	Reiterated Rating	$147.16	$176.00	Overweight
AMGN Amgen	2/10/2025	Boost Price Target	$293.54	$329.00	Overweight
AMPH Amphastar Pharmaceuticals	2/4/2025	Downgrade	$33.39	$36.00	Neutral
COLL Collegium Pharmaceutical	2/4/2025	Lower Price Target	$31.20	$36.00	Neutral
TEVA Teva Pharmaceutical Industries	1/17/2025	Boost Price Target	$21.68	$30.00	Overweight
ITCI Intra-Cellular Therapies	1/14/2025	Reiterated Rating	$127.06	$132.00	Neutral
AVDL Avadel Pharmaceuticals	1/10/2025	Lower Price Target	$7.70	$13.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.